Irinotecan/Temozolomide Antibody in Children with Refractory, Relapsed or Progressive Neuroblastoma


Clinical Trial

Offered by: Nemours
Locations: Delaware Valley, Jacksonville, FL, Orlando, FL, Pensacola, FL

Trial Name

A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma

What is the trial about?

Children's Oncology Group is testing 2 investigational drug combinations to find a new therapy for treating relapsed or refractory neuroblastoma.

Who can participate?

Children who have been diagnosed with relapsed or refractory neuroblastoma will be asked to be in this study.

What is involved?

  • Children in this clinical trial may get treatment on this study for about 1 year. We would like to continue to find out about your child's health every year for about 5 years after he/she enters this study.
  • Some participants will get the drug temsirolimus and some will get ch14.18 and GM-CSF. The rest of the treatment will be the same. 

Contact Nemours Clinical Trials

Trial Name: A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma

Contact Information

(800) 354-5690
clinicaltrials@nemours.org